Based on optical coherence tomography showing average retinal thickness of 299 µm, central thickness of 482 µm, and total retinal volume of 8.46 mm³, is a 700 µg intravitreal Ozurdex (dexamethasone) implant indicated?

OCT Findings Suggest Macular Edema: Ozurdex May Be Indicated, But Critical Context Is Missing

Your OCT shows a central thickness of 482 µm, which indicates significant macular edema that could warrant Ozurdex treatment, but the indication depends entirely on the underlying cause—specifically whether this is from retinal vein occlusion (RVO), diabetic macular edema (DME), or uveitis, as these are Ozurdex's FDA-approved indications.

Critical Missing Information

You've provided OCT measurements but not the diagnosis. Ozurdex (dexamethasone 700 µg implant) is FDA-approved for:

• Macular edema following central or branch retinal vein occlusion (CRVO/BRVO) 1
• Diabetic macular edema (DME) 2
• Non-infectious posterior uveitis 3

Without knowing which condition you have, I cannot definitively recommend treatment.

Interpreting Your OCT Values

Your measurements show:

• Central thickness: 482 µm - This is significantly elevated (normal is approximately 250-300 µm)
• Average thickness: 299 µm - This is at the upper limit of normal
• Total volume: 8.46 mm³ - Mildly elevated

The central thickness of 482 µm indicates clinically significant macular edema that is affecting the foveal center, which is the most vision-critical area.

When Ozurdex Is Indicated Based on Your OCT

For Retinal Vein Occlusion (RVO)

Ozurdex is FDA-approved and effective for RVO-related macular edema 1. The GENEVA study demonstrated significant visual gains at 90 days, though effects diminished by 6 months 1. The COBALT study showed that with retreatment every 4 months, mean visual improvement was 18.6 letters at 6 months and 15.3 letters at 12 months 1.

However, anti-VEGF therapy is preferred as first-line treatment because steroids carry significant risks of cataract (16% at 1 year) and IOP elevation (18% at 1 year) 1. Ozurdex should be considered when:

• Anti-VEGF therapy has failed or shown inadequate response
• Anti-VEGF is contraindicated
• You need rapid response (70% of maximum effect occurs within 1 week) 1

For Diabetic Macular Edema (DME)

Your central thickness of 482 µm meets the threshold for center-involved DME (CI-DME), defined as central thickness ≥2 standard deviations above normal 2.

Anti-VEGF therapy is first-line for DME 2. Multiple high-quality trials show anti-VEGF is more effective than steroids, with patients gaining approximately 2 lines of vision at 2 years 2.

Ozurdex for DME should be reserved for:

• Patients who have failed or had inadequate response to anti-VEGF 4, 5
• Vitrectomized eyes (where anti-VEGF clearance is faster) 6
• Persistent or refractory DME 5

Studies show Ozurdex reduces central thickness significantly by 3 months and improves visual acuity, particularly in diffuse edema patterns 4, 5. However, cystic macular edema is an unfavorable prognostic factor 5.

For Uveitic Macular Edema

If your edema is from non-infectious uveitis, Ozurdex is FDA-approved and can be used as monotherapy 3. Recent data shows mean central thickness decreased from 407 µm to 310 µm at 6 months, with visual improvement from 0.298 to 0.181 logMAR 3.

The implant provides clinically useful but time-limited effect (treatment success estimated at 74% between 3-6 months, dropping to 42% after 9 months), often requiring repeat injection around 6 months 3.

Critical Safety Considerations

Before proceeding with Ozurdex, you must assess:

1. Intraocular pressure (IOP): Baseline IOP is essential. Ozurdex causes IOP elevation in 16-18% of patients, with some reaching >30 mmHg 1, 3. Most cases are medically manageable, but glaucoma patients or those with compromised optic nerves are at higher risk.

2. Lens status: If you're phakic (have your natural lens), cataract formation occurs in 16% at 1 year 1. If you're already pseudophakic (had cataract surgery), this risk is eliminated.

3. Prior treatment history: Have you tried anti-VEGF? For both RVO and DME, anti-VEGF should generally be attempted first unless contraindicated 1, 2.

4. Visual acuity: What is your current vision? If you have good visual acuity (20/25 or better) despite the edema, observation may be appropriate initially 2.

Optimal Retreatment Timing

If Ozurdex is initiated, plan for retreatment at 20 weeks (5 months) based on monthly OCT monitoring 7. The implant shows:

• Lowest mean central thickness at 8 weeks
• Highest visual acuity at 12 weeks
• Sustained modest effect up to 32 weeks
• Optimal functional and structural outcomes with retreatment at 20 weeks 7

Bottom Line Algorithm

Your central thickness of 482 µm indicates significant macular edema that requires treatment, but the specific approach depends on:

1. Identify the underlying cause (RVO, DME, or uveitis)
2. If RVO or DME: Start with anti-VEGF unless contraindicated or previously failed
3. If uveitis: Ozurdex can be first-line
4. If anti-VEGF has failed: Ozurdex is a reasonable next step
5. Before Ozurdex: Check baseline IOP and lens status
6. After Ozurdex: Monitor monthly with OCT and IOP, plan retreatment at 20 weeks if needed

The OCT findings alone support treatment, but you need the diagnosis and treatment history to determine if Ozurdex specifically is the right choice.